14 & 15 September: Demystifying the science behind targeted cancer treatments

Thursday 14 & Friday 15 September, Royal Marsden Hospital, Sutton, London

2-day course: Demystifying the science behind targeted cancer treatments

Level: intermediate

Audience: Ideal for research nurses, clinical nurse specialists, administrative staff, clinical trials coordinators

Description: This 2-day course provides a grounding in cancer biology before moving to descriptions of a wide range of targeted treatments for solid tumours. Also includes mechanisms of drug resistance and an introduction to biomarkers and personalised cancer care. This course goes at a slower pace than many of my other courses, and includes a variety of practical exercises, question sheets and quizzes.

To book, contact: Caroline.Shriver@rmh.nhs.uk 

Please note that this course is free for Royal Marsden/ICR staff but £200 for external delegates

Programme Day 1

Cancer cell biology – key concepts
  • Cells, DNA, chromosomes, genes, proteins
  • Cell division and the cell cycle
  • Cell-cell communication
Cancer genetics
  • Why DNA damage results in cancer
  • Causes of DNA damage
  • Types of DNA damage and their consequences
  • Oncogenes and tumour suppressor genes
The hallmarks of cancer
  • 8 hallmarks of cancer cells
  • The tumour microenvironment
Introduction to targeted cancer treatments
  • The current state of play of targeted cancer treatments
  • Monoclonal antibodies and small molecule kinase inhibitors
  • Comparing monoclonal antibodies and kinase inhibitors
Why the drugs don’t work
  • The complexity of cancer
  • Genetic instability and intratumoural heterogeneity
  • Resistance mechanisms

Programme Day 2

Targeted treatments for solid tumours part 1
  • The importance of growth factor receptors and their downstream pathways as drug targets for solid tumours
  • Growth factor receptor inhibitors in use and trials (e.g. cetuximab, panitumumab, trastuzumab, erlotinib, gefitinib, afatinib, osimertinib, lapatinib)
  • mTOR inhibitors (everolimus), B-Raf inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib)
Targeted treatments for solid tumours part 2
  • VEGF/angiogenesis inhibitors (e.g. bevacizumab, sorafenib, sunitinib, pazopanib, axitinib)
  • PARP inhibitors (e.g. olaparib)
  • ALK inhibitors (e.g. crizotinib, alectinib, ceritinib)
  • Immunotherapy-based cancer treatments (e.g. nivolumab, ipilimumab)
Clinical trials for targeted treatments: a moving picture
  • New paradigms in clinical trial design
  • Clinical development case studies: gefitinib and crizotinib
  • The use of biomarkers to select patients for trials and treatments for patients